Zim Laboratories Ltd (ZIMLAB) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- ZIM Laboratories demonstrated steady growth across key strategic segments in FY25 despite challenges in legacy markets due to currency volatility and geopolitical uncertainty.
- Total revenue for FY25 reached INR 3,790 million, with a 3.2% year-on-year growth. Pharmaceuticals contributed 75% of total revenue, while Nutraceuticals accounted for 25%. Export markets contributed 83% of total revenue.
- Innovation-led segments, New Innovative Products (NIP) and Oral Thin Films (OTF), performed strongly, contributing INR 624 million (16.5%) of total revenue.
- Strategic collaborations were established, including a partnership with a UAE company to expand OTF presence in the GCC region, and a scientific office was set up in the Middle East.
- Key CapEx projects were completed, including a dedicated urology suite for NIP products and a specialized liquid in pellet technology suite.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.